Chargement en cours...
Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic Index of Gene Therapy Vectors for Hemophilia B
Although the desire to develop gene therapy for hemophilia B is high, safety remains a concern. Therefore, improving the therapeutic index of gene therapy vectors is an important goal. Thus, we evaluated the use of three bioengineered factor IX (FIX) variants with improved catalytic activity in the...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Mary Ann Liebert, Inc.
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2861950/ https://ncbi.nlm.nih.gov/pubmed/19196177 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2008.084 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|